Biotechnology contribution to the diagnosis and treatment of chronic kidney disease and frequent comorbidities
Article Sidebar
Main Article Content
Abstract
The aim of this work is to review the contributions of biotechnology, in relation to the treatment, diagnosis and monitoring of chronic kidney disease (CKD) and its most frequent comorbidities, especially anemia. Regarding the treatment, we focus on the development of biopharmaceutical products such as erythropoiesis stimulating agents (ESA), which were the first biopharmaceuticals used to treat anemia associated with chronic kidney disease (CKD). We analyzed their characteristics and their current use after several years of clinical experience, as well as other alternatives in development. We also review different types of biotherapies, the use of bone marrow mesenchymal stromal cells (MSC) and alternative treatments with dietary modifications, which are based on the association between the intestinal microbiota of chronic kidney patients and their pathophysiological conditions. Finally, in relation to diagnosis and monitoring, we refer to the study and validation of diagnostic, predictive and therapeutic biomarkers that have made clinical results possible to be optimized in this type of patient
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
How to Cite
References
Torres Crigna A, Daniele C, Gamez C, et al. Stem/Stromal Cells for Treatment of Kidney Injuries With Focus on Pre-clinical Models. Frontiers in medicine 2018; 5: 179-204.
Lee RH, Seo MJ, Reger RL, et al. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci USA. 2006 103:17438-43.
Reinders ME, de Fijter JW, Roelofs H, et al. Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study. Stem Cells Transl Med. 2013; 2:107-111.
Tan J, Wu W, Xu X, et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney trans-plants a randomized controlled trial. JAMA 2012; 307:1169-1177.
Ciancio G, Sageshima J, Akpinar E, et al. A randomized pilot study of donor stem cell infusion in living-related kidney transplant recipients receiving alemtuzu-mab. Transplantation 2013; 96:800-6.
Van Wyck DB, Alcorn H Jr, Gupta R. Analytical and biological variation in measures of anemia and iron status in patients treated with maintenance hemodialysis. Am J Kidney Dis. 2010; 56:540-546.
Nallu A, Sharma S, Ramezani A, et al. Gut Microbiome in CKD: challenges and opportunities. Transl Res [Internet]. 2017; 179:24-37.
Wish JB. Assessing iron status: Beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol. 2006; 1(Suppl 1): S4-S8.
Ford BA, Coyne DW, Eby CS, et al. Variability of ferritin measurements in chronic kidney disease; implications for iron management. Kidney Int. 2009; 75:104-110.
Chuang CL, Liu RS, Wei YH et al. Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients. Nephrol Dial Transplant. 2003; 18:370-37
Van Wyck DB, Alcorn H Jr, Gupta R. Analytical and biological variation in mea-sures of anemia and iron status in patients treated with maintenance hemodialysis. Am J Kidney Dis. 2010; 56:540-546.
Gaweda AE. Markers of iron status in chronic kidney disease. Hemodialysis International. 2017. S21-27.
Prakoura N, Kavvadas P, Chadjichris-tos CE. Connexin 43: A new therapeutic target against chronic kidney disease. Cellular Physiology and Biochemistry. 2018; 998-1009.